Enhancing the Predictability of Preclinical Development


Preclinical studies enable evaluation of drug candidates for both efficacy and safety within biological model systems. The physiological relevance of the models used can closely mimic biochemical pathways, metabolism, and physiology of human. Hence, primary cells, 3D cell culture/tissues, and cell-based assays comprise relevant model systems.

The webinar focused on preclinical studies within physiological context to better understand the complexity of diseases within the host as well as efficacy and safety of therapeutic intervention.

Firstly, Dr. Seyoum Ayehunie, Vice President, Scientific Research and Development, MatTek Corporation, discussed the functionality and limitations of a novel in vitro 3D primary human cell-based tissue model for drug toxicity and efficacy studies.

Dr. Hyelim Cho, Group Lead, Immunogenicity, Global DMPK Oncology and Rare Diseases, Takeda Pharmaceuticals, explained to the audience why developing a predictive pre-clinical assay is key to success in immuno-oncology drug development.